Investments Include ASPIRE Galderma Rewards Consumer App, Salesforce Expansion, ZO® Skin Health Collaboration and Improved Electronic Medical Record Integration
Galderma will present data on Relfydess® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow’s feet (lateral canthal line
Lausanne, Switzerland – October 10, 2019 – Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis.
Results 61 - 65 of 155
Page 13 of 31
Confirm navigation
You are about to leave the Galderma global site. Are you sure you want to leave this page?
